Gliatech mulls options and bankruptcy
This article was originally published in Clinica
Executive Summary
Gliatech, which develops biosurgery products aimed at inhibiting scarring and adhesions after surgery, is considering its strategic options, including the sale of its Adcon line of products. The company concedes that any proceeds are unlikely to provide sufficient resources to fund operations and that it will probably have to file for bankruptcy protection. Gliatech is also making a "signigicant reduction" in its workforce.
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.